GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy

Cardiovasc Diabetol. 2019 Nov 28;18(1):164. doi: 10.1186/s12933-019-0966-2.

Abstract

Background: Glucagon-like peptide-1 (GLP-1) reduces cardiovascular events in diabetic patients; however, its counter-protective effects have also been suggested in patients with heart failure and the clear explanation for its mechanisms have not yet been offered.

Methods: The effects of GLP-1 analog on cardiac function and energy metabolism, especially glycemic and lipid metabolisms were elucidated using non-diabetic J2N-k hamsters which showed spontaneous dilated cardiomyopathy. J2N-k hamsters were treated with PBS (HF group), low-dose (HF-L group) or high-dose liraglutide (HF-H group).

Results: In failing heart, GLP-1 analog exerted further deteriorated cardiac function (e.g. positive and negative dP/dt; p = 0.01 and p = 0.002, respectively) with overt fibrosis and cardiac enlargement (heart/body weight, 5.7 ± 0.2 in HF group versus 7.6 ± 0.2 in HF-H group; p = 0.02). The protein expression of cardiac muscles indicated the energy starvation status. Indirect calorimetry showed that failing hearts consumed higher energy and carbohydrate than normal hearts; moreover, this tendency was augmented by GLP-1 analog administration. Upon 10% glucose solution loading with GLP-1 analog administration (HF-H-G group) as complementary experiments, the cardiac function and fibrosis significantly ameliorated, whereas carbohydrate utilization augmented further and lipid utilization reduced more. The prognosis of HF-H-G group also significantly improved (p = 0.025).

Conclusions: Glucagon-like peptide-1 analog caused the relative but desperate shortage of glycemic energy source for the failing cardiac muscles and it may restrict ATP synthesis, resulting in cardiac function deterioration. Therefore, appropriate energy supply and amount of carbohydrate intake should be carefully considered when administrating incretin-related drugs to patients with heart failure.

Keywords: GLP-1; Heart failure; Metabolism.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Animals
  • Cardiomyopathy, Dilated / complications
  • Cardiomyopathy, Dilated / metabolism*
  • Cardiomyopathy, Dilated / physiopathology
  • Cricetinae
  • Disease Models, Animal
  • Energy Metabolism / drug effects*
  • Fibrosis
  • Heart Failure / etiology
  • Heart Failure / metabolism*
  • Heart Failure / physiopathology
  • Incretins / toxicity*
  • Liraglutide / toxicity*
  • Male
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Risk Assessment
  • Stroke Volume / drug effects
  • Ventricular Function, Left / drug effects
  • Ventricular Pressure / drug effects
  • Ventricular Remodeling / drug effects*

Substances

  • Incretins
  • Liraglutide
  • Adenosine Triphosphate